Ipamorelin — Indexed Studies

Doping control container for urine stabilization: a pilot study.

Tsivou M, Giannadaki E, Hooghe F et al.

Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.

Beck DE, Sweeney WB, McCarter MD et al.

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

Gobburu JV, Agersø H, Jusko WJ et al.

A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

Coutinho LFD, DE Oliveira Neves LF, Camilo RP

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.

Lu Z, Ngan MP, Liu JYH et al.

The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.

Gouda M, Ganesh CB

Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.

N Mohammadi E, Louwies T, Pietra C et al.

Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor.

Fowkes MM, Lalonde T, Yu L et al.

A stable meta-carborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor.

Worm DJ, Els-Heindl S, Kellert M et al.

Glycine-modified growth hormone secretagogues identified in seized doping material.

Gajda PM, Holm NB, Hoej LJ et al.

Analysis of new growth promoting black market products.

Krug O, Thomas A, Malerød-Fjeld H et al.

Structure-activity relationship for peptídic growth hormone secretagogues.

Ferro P, Krotov G, Zvereva I et al.

Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.

Thomas A, Görgens C, Guddat S et al.

Solid-phase extraction of small biologically active peptides on cartridges and microelution 96-well plates from human urine.

Semenistaya E, Zvereva I, Krotov G et al.

Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.

Semenistaya E, Zvereva I, Thomas A et al.

Detection of GHRP-2 and GHRP-6 in urine samples from athletes.

Cox HD, Hughes CM, Eichner D

A high-throughput LC-MS/MS screen for GHRP in equine and human urine, featuring peptide derivatization for improved chromatography.

Timms M, Hall N, Levina V et al.

Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry.

Kwok WH, Ho EN, Lau MY et al.

Metabolism of growth hormone releasing peptides.

Thomas A, Delahaut P, Krug O et al.

Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry.

Thomas A, Walpurgis K, Krug O et al.

Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.

Greenwood-Van Meerveld B, Tyler K, Mohammadi E et al.

Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry.

Thomas A, Höppner S, Geyer H et al.

Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.

Venkova K, Mann W, Nelson R et al.

Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats.

Aagaard NK, Grøfte T, Greisen J et al.

Seabream ghrelin: cDNA cloning, genomic organization and promoter studies.

Yeung CM, Chan CB, Woo NY et al.

Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats.

Adeghate E, Ponery AS

Stimulation of growth hormone secretion from seabream pituitary cells in primary culture by growth hormone secretagogues is independent of growth hormone transcription.

Chan CB, Fung CK, Fung W et al.

Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue.

Johansen PB, Segev Y, Landau D et al.

The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency.

Peschke B, Ankersen M, Bauer M et al.

Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.

Jiménez-Reina L, Cañete R, de la Torre MJ et al.

The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.

Andersen NB, Malmlöf K, Johansen PB et al.

Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin.

Hansen TK, Ankersen M, Raun K et al.

Structural similarity of ghrelin derivatives to peptidyl growth hormone secretagogues.

Matsumoto M, Kitajima Y, Iwanami T et al.

Do growth hormone-releasing peptides act as ghrelin secretagogues?

Ahnfelt-Rønne I, Nowak J, Olsen UB

Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.

Lall S, Tung LY, Ohlsson C et al.

The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.

Svensson J, Lall S, Dickson SL et al.

Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats.

Malmlöf K, Johansen PB, Haahr PM et al.

Pharmacological characterisation of a new oral GH secretagogue, NN703.

Hansen BS, Raun K, Nielsen KK et al.

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.

Johansen PB, Nowak J, Skjaerbaek C et al.

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.

Johansen PB, Hansen KT, Andersen JV et al.

Ipamorelin, the first selective growth hormone secretagogue.

Raun K, Hansen BS, Johansen NL et al.

Novel orally active growth hormone secretagogues.

Hansen TK, Ankersen M, Hansen BS et al.

A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.

Ankersen M, Johansen NL, Madsen K et al.

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Rahman OF, Lee SJ, Seeds WA

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Mayfield CK, Bolia IK, Feingold CL et al.

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

Sinha DK, Balasubramanian A, Tatem AJ et al.

[Ghrelin-related drugs: clinical perspectives].

Shimatsu A

[Structure-activity relationship of ghrelin].

Minamitake Y